CGTLive’s Weekly Rewind – June 2, 2023


Review top news and interview highlights from the week ending June 2, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA Accepts Lifileucel's BLA for Advanced Melanoma With Priority Review

The BLA has a PDUFA action date of November 25, 2023.

2. Joseph Fraietta, PhD, on Investigating Molecular Pathways of CAR T-Cell Resistance

The assistant professor of microbiology at Penn Medicine discussed research into characterizing type 1 interferon and EGR2 signaling and their effects on CAR T-cell activation.

3. Genprex’s NSCLC Immunogene Therapy Trial Cleared to Begin Phase 2 Expansion Portion

Genprex also announced preliminary data from the phase 1 portion of the trial evaluating Reqorsa, which is being presented at ASCO’s 2023 meeting.

4. Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity

The scientist at Senti Biosciences discussed developing small molecule-regulated gene circuits.

5. PepGen’s Myotonic Dystrophy Oligonucleotide Trial Stalls

In more positive news, the company’s phase 2 trial for treating DMD will enroll patients in the second half of 2023.

Related Videos
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
© 2024 MJH Life Sciences

All rights reserved.